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Introduction
Glucuronidation is one of the major phase II conjugation reactions catalyzed by a family of uridine 5'-diphospho-(UDP)-glucuronosyltransferases (UGTs), which are expressed primarily in the liver and in extrahepatic tissues such as the intestine and kidney (Liston et al., 2001) . UGTs are involved in the metabolism of a large number of drugs and endogenous substances by transferring glucuronic acid from its cofactor uridine 5′-diphosphoglucuronic acid (UDPGA) to substrates, thereby transforming them into hydrophilic glucuronides, which can be eliminated easily via biliary and renal routes (Guillemette, 2003) .
Sarpogrelate, (R,S)-1-[2-[2-(3-methoxyphenyl)ethyl] phenoxy]-3 (dimethylamino)-2-propyl
hydrogen succinate, is a competitive 5-hydroxytryptamine (5-HT) receptor antagonist that inhibits responses to 5-HT mediated by 5-HT 2A receptors, including platelet aggregation and vasoconstriction (Hara et al., 1991; Rashid et al., 2003; Nishihira et al., 2006) . This drug has been used to treat patients with peripheral arterial disease (Furukawa et al., 1991) and is equivalent to aspirin in preventing recurrence of cerebral infarction with significantly fewer bleeding events (Shinohara et al., 2008) . Sarpogrelate is rapidly metabolized to its active metabolite (M-1) via enzymatic hydrolysis (Saini et al., 2004) and disappears from the plasma more rapidly in comparison to the duration of its pharmacological effect. Although plasma concentrations of M-1 are <1/10 of those of sarpogrelate, pharmacokinetic-pharmacodynamic modeling has demonstrated that M-1 is a more effective inhibitor of platelet aggregation than sarpogrelate (Shimizu et al., 1999) . Sarpogrelate and its metabolites are primarily excreted into the bile as glucuronide conjugates, suggesting that glucuronidation is a critical step governing This article has not been copyedited and formatted. The final version may differ from this version. In this study, we identified the human UGTs responsible for the metabolism of sarpogrelate and M-1 into their glucuronide metabolites using in vitro systems. The structures of metabolites were tentatively characterized on the basis of mass and nuclear magnetic resonance (NMR) spectrometry and metabolic screening was performed with a battery of recombinant human UGTs to identify the specific UGT isoforms involved in N-and O-glucuronidation. Kinetic enzymatic studies were performed with human liver microsomes (HLMs) and with those UGT enzymes that catalyze glucuronidation of sarpogrelate active metabolites. Inhibition of UGTglucuronidation activity and correlations with known marker activities in HLMs were determined using known high-affinity UGT substrates to facilitate identification of the UGT isoforms involved in M-1 glucuronidation. In addition, the feasibility of using M-1 as an isoform specific probe substrate was evaluated because UGT isoform-specific substrates are not well characterized.
This article has not been copyedited and formatted. The final version may differ from this version. 
Synthesis of M-1 Enantiomers.
(S)-M-1 was prepared using the following procedure. 2-[2-(3-methoxyphenyl)ethyl]phenol (200 mg, 0.876 mmol) was dissolved in 5ml of ethanol and NaOH (42 mg, 1.051 mmol) was added. After stirring for 20 min at room temperature, (R)-epichlorohydrin (0.2 ml, 2.628 mmol) was added dropwise. The resulting mixture was stirred for 9 h, solvent was evaporated, and then the residue was dissolved in ethylacetate. The resulting solution was washed with 1N NaOH, dried over MgSO 4 , and concentrated in vacuo. The residue was purified by column chromatography (n-hexane : ethylacetate = 10 : 1) to afford (S)-2-[2-(2-(3-methoxy)phenylethyl)phenoxy]methyloxirane (190 mg 
(R)-M-1 was also prepared using the same procedure except for using (S)-epichlorohydrin. of the liver homogenate, as described previously (Shin et al., 1999) . Ten different HLMs were pooled and used for the experiments. In the case of rats, liver tissues from 6 rats were pooled for the preparation of liver microsomes. With the exception of adding UGT-isoform-specific inhibitors, all other incubation conditions were similar as described above.
Preparation of
Glucuronidation of
Correlation Experiments. M-1 (50 μ M) was incubated with microsomes from 20 different human livers to examine the formation of SMG1, SMG2 and SMG3 from M-1, relative to specific UGT isoform activity. The activity of each UGT isoform was assessed by LC-MS/MS as described previously for propofol glucuronidation (UGT1A9) (Court, 2005) and trifluoperazine glucuronidation (UGT1A4) (Uchaipichat et al., 2006a) with slight modifications; 10 μM concentrations were used for both compounds and the incubation time was 30 min. The correlation coefficients between the formation rates of M-1 glucuronides and the activities of each UGT isoform in a panel of 20 HLMs were calculated by Spearman correlation coefficient analysis using the SAS software (SAS Institute, Cary, NC). P values < 0.05 were considered to be statistically significant.
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Results
Glucuronidation of Sarpogrelate and M-1 in Human and Rat Liver Microsomes. Two metabolites (SG1 and SG2) were generated after incubation of sarpogrelate with HLMs in the presence of UDPGA, whereas one metabolite (SG1) was generated with rat liver microsomes (RLMs) (Fig. 2) . These metabolites were identified as glucuronide conjugates by full-scan mass analysis, which showed the addition of a 176 Da glucuronic acid to the parent sarpogrelate (m/z 430). Incubation of M-1 with HLMs in the presence of UDPGA resulted in the formation of three metabolites (SMG1, SMG2, and SMG3). However, only two metabolites (SMG1 and SMG3) were identified when M-1 was incubated with RLMs ( Fig. 2) . M-1 metabolites were also confirmed as glucuronide conjugates as judged by addition of 176 Da to the parent M-1 (m/z 506). The subsequent product ion mass spectra of the metabolites generated identical fragment ion patterns, which showed the major fragment ion at m/z 330, indicating loss of a glucuronide moiety (Supplemental Fig. 1 ).
Structure of M-1 Glucuronides. SMG1, SMG2, and SMG3 were isolated and their structures determined by comparing their proton NMR spectra to that of M-1 (Fig. 3 ). SMG1 and (Fig. 4) . Sarpogrelate can be enzymatically transformed to M-1 by ester hydrolysis of succinic ester. Furthermore, sarpogrelate can be spontaneously hydrolyzed to M-1 in the aqueous phase (Kamatsu et al., 1992) . To further characterize the nature of SMG2, the hydrolysis products of sarpogrelate glucuronides were characterized. It is reasonable to assume that N-glucuronide of M-1 can be generated only from a sarpogrelate N-glucuronide via hydrolysis of the succinic ester. HPLC fractions containing SG1 and SG2 were left at room temperature for 48 h and re-injected into an HPLC column. Only SMG2 was detected after partial hydrolysis of SG2, whereas SMG1 and SMG3 were not detected in the hydrolysis products of SG1 or SG2 (Supplemental Fig. 2 ). primarily by UGT1A9 with minor contributions by UGT2B4 and 2B7, whereas SMG3 formation was mediated predominantly by UGT2B4 and 2B7. In contrast, N-glucuronide SMG2 was generated only by UGT1A4. The formation of SMG1, SMG2, and SMG3 from M-1 was assessed using UGT-isoform-selective inhibitors or substrates. SMG1 formation was inhibited by the UGT1A9 inhibitor niflumic acid, while formation of SMG2 and SMG3 were not affected (Fig. 6 ). The formation of SMG2 was preferentially inhibited by hecogenin, a known UGT1A4
Identification of UGT Isoforms Involved in
１ ４
inhibitor, whereas SMG3 formation was inhibited by fluconazole, a known inhibitor of UGT2B4 and 2B7. Correlation analyses with activities of known marker UGT isoforms were performed to confirm the involvement of UGT1A4 and 1A9 in the formation of M-1 glucuronides. As shown in Fig. 7 , significant correlations were found between SMG1 formation rates and UGT1A9-mediated propofol glucuronidation (r = 0.6269, P < 0.0031) and between SMG2 formation rates and UGT1A4-medated trifluoperazine glucuronidation (r = 0.6623, P < 0.0015).
Enzyme Kinetic Analysis. Kinetic analyses of formation of M-1 glucuronides were performed with pooled HLMs using 10-1000 showed 17-fold higher Vmax than did UGT2B4-mediated formation of SMG1. The Cl int of SMG1 by UGT1A9 was three fold greater than that by UGT2B4. However, the Cl int of SMG3 by UGT2B4 was similar to that of SMG1 formation by UGT2B4. Based on the Cl int data, UGT2B7
was considered to make a greater contribution to SMG3 formation did than UGT2B4.
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Discussion
The glucuronidation of sarpogrelate and its active metabolite M-1 is an important part of sarpogrelate disposition in humans. In experimental rats, the majority of circulating M-1 in the plasma after oral administration was determined to be glucuronide conjugates (Takada et al., 1997) . In addition, metabolic analysis demonstrated that ~76% of M-1 was present as a glucuronide, whereas only 24% was present as free M-1 in bile from rats treated with sarpogrelate. Our results also suggest M-1 glucuronidation to be more efficient than that of sarpogrelate. Intrinsic clearance rates of M-1 O-glucuronides (SMG1 and SMG3) and Nglucuronide (SMG2) were 10-fold higher than those of the sarpogrelate O-glucuronide (SG1) and N-glucuronide (SG2) in HLMs. Understanding the nature of M-1 glucuronidation is of interest because M-1 is known to be more pharmacologically active than its parent compound sarpogrelate.
In the present investigation, we demonstrated that sarpogrelate is metabolized to Oglucuronide (SG1) and N-glucuronide (SG2) whereas M-1 is transformed into two Oglucuronides (SMG1 and SMG3) and a N-glucuronide in the presence of UDPGA in HLMs (Fig.   1 ). The structures of M-1 glucuronides were characterized by mass and 1 H-NMR spectroscopy.
No structural information could be obtained from product ion mass spectra of M-1 glucuronides because all were almost identical. NMR spectra showed that the 1 H chemical shifts of the anomeric proton of SMG1 and SMG3 were similar (4.45 and 4.64 ppm), whereas that of SMG2 was farther downfield, at 4.89 ppm. In general, the chemical shifts of anomeric protons in Oglucuronides were 4.4-4.6 ppm, whereas those in N-glucuronides were 5.1-5.5 ppm (Zhu et al., 2008; Pallmann et al., 2010; Alonen et al., 2008) . Accordingly, SMG1 and SMG3 were This article has not been copyedited and formatted. The final version may differ from this version. was further supported by species differences in the formation of SMG2; SMG2 was generated only by HLMs and not by RLMs (Fig. 2) . The formation of quaternary ammonium glucuronides from tertiary amines is a reaction largely restricted to humans and generally not observed in animal species, including rats, mice, dogs, and monkeys (Kaivosaari et al., 2011; Soars et al., 2001; Kaku et al., 2004) . The structure of sarpogrelate glucuronides was confirmed by analysis of their hydrolysis products. Sarpogrelate can be hydrolyzed at the ester moiety in its chemical structure, leading to formation of M-1. The conversion of SG1 to M-1 in an aqueous solution indicated that SG1 was sarpogrelate O-glucuronide and the hydrolysis of the succinic glucuronide moiety from SG1 resulted in the formation of M-1. However, SG2 was hydrolyzed to SMG2 but not to M-1, suggesting that SG2 was a quaternary ammonium glucuronide of sarpogrelate and that a glucuronide moiety remained after the hydrolysis of succinic ester, leading to the formation of the N-glucuronide of M-1. The structure of SMG2 was further supported by the fact that SG2 formation occurred in HLMs but not in RMLs. 
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isoforms showed that only UGT1A4 catalyzed N-glucuronidation of M-1. UGT1A4 is the major isoform involved in the glucuronidation of tertiary amines, including 1′-hydroxymidazolam, imipramine, and tamoxifen (Green and Tephly, 1996; King et al., 2000; Zhu et al., 2008) . No UGT1A4 ortholog is present in rat tissues (King et al., 2000) . Incubation of sarpogrelate or M-1
with RMLs in the presence of UDPGA generated O-glucuronides (SG1, SMG1, and SMG3) but not N-glucuronides (SG2 and SMG2), consistent with previous reports that only the UGT1A4 isoform catalyzes N-glucuronidation of tertiary amines. SMG1 formation was catalyzed mainly by UGT1A9 with minor contributions by UGT 2B4 and 2B7, whereas SMG3 was generated by both UGT2B4 and 2B7, suggesting considerable stereo-selectivity in M-1 O-glucuronidation.
UGT1A9 played a major role in glucuronidation of R-enantiomer whereas UGT2B4 and 2B7
were preferentially involved in glucuronidation of S-enantiomer of M-1.
Secondly, inhibition of M-1 glucuronide formation was evaluated using UGT-isoformspecific substrates and/or inhibitors. SMG1 formation was strongly inhibited by niflumic acid (1 μM, ~80%), a selective inhibitor of UGT1A9 (Gaganis et al., 2007; Miners et al., 2010) , whereas the formation of SMG3 was inhibited by fluconazole (3 mM, ~90%), a selective inhibitor of UGT2B7 (Uchaipichat et al., 2006b; Raungrut et al., 2010) (Fig. 7) . SMG2 formation was markedly inhibited by hecogenin (10 μM, ~ 60%), a potent UGT1A4 inhibitor (Uchaipichat et al., 2006a) . Thirdly, correlations between M-1 glucuronidation and known UGT isoform activities were assessed using a panel of HLMs. Significant correlations were observed between the SMG1 formation and UGT1A9-mediated propofol glucuronidation rates (Court, 2005) 
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